DMII SEC filings, in plain English
Everything Drugs Made In America Acquisition II Corp. has filed with the SEC that we hold — 40 filings, newest first, 38 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Quarterly Report (Form 10-Q) for Drugs Made In America Acquisition II Corp. for the period ended June 30, 2026. Redeemable ordinary shares increased from $504,933,800 (redemption value $10.10 per share) at December 31, 2025 to $513,882,333 (redemption value $10.28 per share) at June 30, 2026, reflecting $8,948,533 in accretion resulting from Trust Account interest earnings. The Company issued $450,000 in promissory notes (Alpha Promissory Notes) in March 2026, including a $150,000 Bridge Note and a $300,000 Second Note, convertible at a 35% discount to market price upon a business combination. A CEO Compensation Agreement was entered on April 22, 2026, granting the CEO $4,500/month compensation and 250,000 ordinary shares issuable upon a definitive agreement. The Consulting Agreement for the CFO was updated on April 22, 2026, increasing the share grant from 100,000 to 175,000 ordinary shares. The Administrative Support Agreement with the sponsor was cancelled in March 2026; the Company reclassified $30,000 as a capital contribution. The Company recorded a $782,113 reserve for credit losses against the Due from Sponsor, as the sponsor has not repaid the outstanding balance despite board directive. Why it matters: The accretion to redemption value signals the trust is generating interest. The convertible promissory notes from a new investor, Alpha Multi Family Office, with a Definitive Investment and Sponsor Transition Agreement, point to active deal financing and sponsor transition efforts. The due-from-sponsor balance of $782,113 remains fully reserved, indicating ongoing sponsor conduct concerns. The management agreements (CEO/CFO) with stock grants tied to a definitive agreement suggest the Company is preparing for a transaction. The working capital deficit and going concern disclosure highlight that cash runway is tight and the deadline (24 months from September 2025, i.e., September 2027) is approaching.
What changed vs 2026-05-14trust $509.4M → $513.9M +1%trust account, going-concern doubt, sponsor loans outstanding +21 moved · 4 with no prior record of ours
- Trust account
- $509.4M$513.9M
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $325K · unchanged
- Mandate language
- we intend to focus our search for businesses in the pharmace… · unchanged
- Redeemable shares
- 50.0M · unchanged
SpacBrain reads this as $4,508,683 was added to the trust between the two filings.
The clause “14 Total Current Assets 217,823 26,037 Non-current Assets: Cash and investments held in Trust Account 513,882,333 504,933,800 Total Non-current Assets 513,882,333 504,933,800 TOTAL ASSETS $ 514,100,156 $ 504,959,837 LIABILITIES, ORDINARY”…
The clause …“except for the purpose of liquidating. In connection with our assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of”…
The clause …“determines to not proceed with such Initial Public Offering. The Company had borrowed $ 325,000 under the promissory note, which the Company repaid on September 29, 2025. As such, no amounts are outstanding as of June 30, 2026 and”…
The clause “1, 2025 there were 13,700,000 ordinary shares issued and outstanding, excluding 50,000,000 shares subject to possible redemption, of which an aggregate of up to 1,875,000 ordinary shares were surrendered or forfeited in connection with”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed by Drugs Made In America Acquisition II Corp., a blank check company (SPAC) still searching for a target business combination. Trust value per share increased from $10.10 to $10.19 due to $4.44M interest earned; sponsor owes $782K to company (fully reserved as credit loss), with only $30K repaid in Q1; working capital deficit of $315K; issued $450K in convertible notes to Alpha Multi Family Office, which also executed a Definitive Investment and Sponsor Transition Agreement; prior CEO resigned Feb 28, 2026; new CEO Roger Bendelac appointed; sponsor standstill agreement prevents voting; material weakness in internal controls disclosed; going concern doubt raised; no business combination target announced. Why it matters: The sponsor's inability to repay the due from sponsor raises serious governance and liquidity concerns. The new financing from Alpha Multi Family Office and sponsor transition agreement could signal a pending deal or change in control. The trust value is growing, but the company's cash position remains thin. The material weakness in internal controls and going concern doubt increase risk for shareholders considering redemption.
What changed vs 2025-11-18trust $500.1M → $509.4M +2%trust account, going-concern doubt, sponsor loans outstanding +21 moved · 4 with no prior record of ours
- Trust account
- $500.1M$509.4M
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $325K · unchanged
- Mandate language
- we intend to focus our search for businesses in the pharmace… · unchanged
- Redeemable shares
- 50.0M · unchanged
SpacBrain reads this as $9,264,295 was added to the trust between the two filings.
The clause “14 Total Current Assets 351,761 26,037 Non-current Assets: Cash and investments held in Trust Account 509,373,650 504,933,800 Total Non-current Assets 509,373,650 504,933,800 TOTAL ASSETS $ 509,725,411 $ 504,959,837 LIABILITIES, ORDINARY”…
The clause …“except for the purpose of liquidating. In connection with our assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of”…
The clause …“determines to not proceed with such Initial Public Offering. The Company had borrowed $ 325,000 under the promissory note, which the Company repaid on September 29, 2025. As such, no amounts are outstanding as of March 31, 2026 and”…
The clause “1, 2025 there were 13,700,000 ordinary shares issued and outstanding, excluding 50,000,000 shares subject to possible redemption, of which an aggregate of up to 1,875,000 ordinary shares were surrendered or forfeited in connection with”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: SEC Form 8-K reporting the entry into two material definitive agreements dated April 22, 2026: an updated Statement of Work between Drugs Made In America Acquisition II Corp. and Titan Advisory Services LLC regarding CFO Saleem Elmasri, and a CEO Compensation Agreement between the Company and Aleutian Equity Holdings LLC for Roger Bendelac. Per the Company’s filing, the updated Statement of Work retains Elmasri’s monthly compensation at $3,500 but amends the equity component from 100,000 to 175,000 ordinary shares. Exhibit 10.1 states these shares are earned upon execution of a definitive agreement and issuable within ten days after business combination closing, while all prior unpaid compensation remains a binding obligation. The separate CEO Compensation Agreement (Exhibit 10.2) formalizes compensation for Roger Bendelac, who the filing notes was appointed Chief Executive Officer on February 28, 2026. Bendelac receives $4,500 per month, with $2,500 payable currently and up to $2,000 deferrable based on cash flow; the filing specifies deferred amounts accrue as binding obligations. Bendelac is awarded 250,000 ordinary shares earned upon execution of a definitive agreement and issuable within ten days thereafter. Former Chief Executive Officer Lynn Stockwell is referenced in the filing as the designated transferor for the original share grant provision. Both agreements include indemnification covering securities-related claims (excluding gross negligence or misconduct), New York governing law, and a dispute resolution clause mandating mediation followed by binding arbitration. Why it matters: The filing does not alter the SPAC’s redemption calendar, trust account distribution mechanics, or extension procedures. Instead, it establishes new post-combination financial and equity obligations that directly impact deal economics. Per the exhibits, the Company binds itself to ongoing monthly cash commitments of $3,500 and $4,500, potential $2,000 monthly deferrals, and two discrete equity grants: 175,000 ordinary shares to Elmasri and 250,000 ordinary shares to Bendelac. Because these share awards vest exclusively upon executing a definitive agreement, they function as transaction-triggered incentives that will dilute public shareholders and reduce pro forma net tangible book value at closing. While these terms do not impact the stated trust reserve or trigger automatic redemptions, they confirm management is financially incentivized to complete a business combination and introduces fixed compensation liabilities that sponsors and public holders should model alongside any expected PIPE financing or working capital arrangements.
What changed: 10-K Annual Report for the fiscal year ended December 31, 2025. Trust account holds $504,933,800 ($10.10 per public share, up from $10.00 IPO price). Sponsor withdrew $1,345,844 from working capital, leaving $812,113 unrecoverable due from sponsor; full reserve taken. CEO Lynn Stockwell removed on Feb 28, 2026 after sponsor unable to repay; Roger Bendelac appointed CEO. Sponsor entered standstill agreement. Bridge financing of $150,000 (Mar 11) and $300,000 (Mar 30) from Alpha Multi Family Office secured; total planned $1.4M. No business combination target selected. Working capital deficit of $274,827; going concern substantial doubt. Why it matters: Sponsor misconduct (unauthorized withdrawal, inability to repay) signals severe governance failure and cash crisis. With only $223 cash and minimal working capital, the SPAC may struggle to fund operations and due diligence before the 24-month deadline (Sept 2027). Trust value per share is $10.10, but the sponsor's indemnification capacity is in doubt. New CEO and financing provide some hope, but no target or definitive agreement exists.
What changed: A Form 8-K Current Report classified as a routine compliance exhibit filing documenting the execution of a Definitive Investment and Sponsor Transition Agreement and an Interim Convertible Note. The Definitive Investment and Sponsor Transition Agreement, signed by Chief Executive Officer Roger E. Bendelac and Investor CEO Alon Izidor Tal, establishes a $1,400,000 financing commitment. Per Section 3 and Exhibit A, $150,000 was previously received, $300,000 was issued as a March 30, 2026 Interim Convertible Note, and $950,000 remains reserved in escrow. The note, bearing no interest and maturing in nine months, converts at a 35% discount to post-merger market value solely at the investor’s option. Section 7 and Exhibit A confirm the notes constitute no claim against the trust account. Section 6 documents the existing sponsor as 'non-performing and subject to legal constraints,' permits cooperative restructuring, facilitates sponsor interest transfers when legally allowed, and grants the investor the right to offer to acquire sponsor stakes. The agreement targets an agreement-in-principle within four months under a six-month exclusivity window. Expenses exceeding $50,000 require advance notice. A separate $100,000 advisory fee supports Transaction Advisor S.E.E Capital Partners Ltd., signed by president Anastasio Carayanni. Why it matters: This disclosure modifies the SPAC’s capital runway and governance posture without altering redemption schedules, trust account balances, or extension mechanics. The sponsor characterization and transition protocol introduce a contractual pathway for leadership change or interest consolidation, potentially accelerating approval processes while raising succession dilution considerations for public holders. The $1,400,000 financing tranches and 35% discount conversion pricing establish quantifiable future share count expansion upon consummation, whereas the explicit trust account exclusion preserves standard redemption liquidity parameters. The nine-month maturity combined with the four-month timeline creates a hard execution constraint; failure by the investor triggers Section 9 replacement financing clauses, imposing 15% per annum interest on disbursed capital while waiving penalties on unfunded reserves. Operational control stays with the Board per Section 11, but the investor maintains mandatory consultation rights, creating a parallel oversight track that may influence deal pacing and PIPE coordination strategies.
What changed: Form 12b-25 Notification of Late Filing (routine compliance exhibit) requesting relief under Securities and Exchange Commission Rule 12b-25 to postpone submission of the Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Chief Executive Officer Roger E. Bendelac signed the notification on April 1, 2026, stating the registrant could not timely compile all financial statement information and related disclosures without unreasonable effort or expense. The company now expects to file the Annual Report on or before April 15, 2026. Bendelac certifies that all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months have been filed, and the registrant does not anticipate reflecting any significant change in results of operations in the subject report. The SPAC retains SEARCHING status, and the reported trust per share remains $10.28. No charter amendment, explicit redemption deadline modification, or shareholder extension vote is recorded in this filing. Why it matters: For investors monitoring redemption calendars, extension triggers, and sponsor execution, a late-form filing halts the disclosure pipeline required to evaluate a proposed business combination or vote on a trust extension. Because Bendelac attributes the delay to compiling financial data rather than market dynamics or target scarcity, sponsors face scrutiny over auditor readiness, internal controls, and whether acquisition due diligence can advance while baseline financials remain unresolved. The document contains no claims regarding customers, revenue, market size, commercial strategy, technology development, partnership agreements, active litigation, or personnel changes; it consists exclusively of procedural certification and timeline recalibration. Without the audited 10-K, shareholders cannot verify trust allocation, assess whether remaining liquidity covers potential extension fees or liquidation costs, or time redemptions against audited NAV adjustments. This procedural hold materially extends the window during which liquidation risk accumulates and decision-making on capital deployment remains paused until sponsor disclosures resume.
What changed: A Form 8-K current report accompanied by Exhibits 10.1 (Letter of Intent), 10.2 (Addendum to Letter of Intent), and 10.3 (Bridge Financing Convertible Promissory Note) detailing SPAC bridge capital arrangements. This document is a routine compliance exhibit (Form 8-K) reporting the entry into agreements for bridge financing. Regarding redemption deadlines, trust value, extensions, deal progress, and sponsor conduct: the filing contains no information on shareholder redemption rights, trust account balances, extension amendments, identified merger targets, or modifications to existing deadlines. The Company stated it intends to use the bridge loan proceeds for 'accounting expenses, audit expenses and other expenses related to the Business Combination' and regulatory costs to maintain its NASDAQ listing, which supports ongoing operations but does not accelerate or alter any de-SPAC timeline. Chief Executive Officer Roger Bendelac signed the Letter of Intent, the Addendum, and the Bridge Note, demonstrating active capital raising efforts. The Addendum explicitly clarifies that S.E.E Capital Partners Ltd. 'acts solely as advisor' and 'shall not be deemed the sponsor or issuer.' Regarding other substance: The original Letter of Intent (dated March 5, 2026) outlined a proposed Senior Convertible Note investment of USD $1,500,000. The Addendum (dated March 9, 2026) modified the aggregate financing to $1,400,000, with the parties acknowledging the $100,000 difference represents 'due diligence and negotiation costs associated with the Investor’s advisor,' which the Investor alone agreed to settle with the Transaction Advisor. The document records an initial bridge note of $150,000 issued on March 11, 2026, functioning as a deposit toward the $1,400,000 total. The remaining $1,250,000 is contingent on a definitive Convertible Note Purchase Agreement. A minimum funding milestone requires that 'at least $400,000 in aggregate funding shall be disbursed to the Company on or prior to March 30, 2026.' Upon consummation of a business combination, the Investor may convert the outstanding principal at a 35% discount to the combined entity's market price. Disbursements will require joint authorization from an IOLA escrow account. The note bears no interest, matures nine months from issuance unless converted or credited, and is governed by Cayman Islands law. No claims regarding customers, revenue, market size, technology, strategic partnerships, litigation, or personnel changes appear in the text. Why it matters: Although the filing does not update the redemption calendar, trust mechanics, or de-SPAC schedule, it materially affects near-term liquidity and listing survival. The mandatory $400,000 disbursement by March 30, 2026 establishes a concrete cash-inflow checkpoint. The 35% conversion discount and sole-discretion conversion rights favor the lender upon a future combination, potentially diluting existing shareholders at the time of the event. Tracking whether the $1,250,000 remainder closes and how the escrow release mechanism operates will indicate whether management is preserving runway for active target evaluation or merely covering administrative overhead ahead of potential deadlines.
What changed: A Form 8-K current report detailing the departure of senior officers, the appointment of a replacement Chief Executive Officer, and disclosures regarding related-party working capital transactions. The filing reports that the Sponsor withdrew an aggregate $1,100,000 from the Company's working capital account between the September 26, 2025 initial public offering and September 30, 2025. Document breakdowns indicate $325,000 repaid an outstanding working capital note to the Sponsor, $208,000 repaid offering costs and expenses to the Sponsor, and a $566,269 overpayment to the Sponsor. Additionally, between September 30, 2025 and December 31, 2025, the Sponsor withdrew no less than $200,000 to pay for expenses unrelated to the Company. The Board directed repayment of this 'Overpayment Amount,' but the Board and Chief Financial Officer learned on February 12, 2026 that the Sponsor could not return it. Consequently, on February 28, 2026, the Board removed Lynn Stockwell as Chief Executive Officer, Executive Chair of the Board, and a Board member. Roger Bendelac was appointed Chief Executive Officer effective the same date, with compensation undetermined. Why it matters: The Sponsor's diversion of working capital for non-company purposes and subsequent failure to repay directly threatens the liquidity pool backing the trust account, posing a material risk to shareholder redemption values and potentially complicating the remaining search timeline. The abrupt leadership change during the SEARCHING phase introduces governance turbulence and execution uncertainty. While the filing does not adjust official redemption deadlines or recalculate per-share trust value, the unresolved status of the unrecovered funds highlights sponsor conduct that could delay or derail a future business combination. The appointment of Roger Bendelac—a 69-year-old consultant with over 30 years of investment banking and advisory experience—signals an attempted operational reset, though his specific compensation arrangements remain pending Board approval.
What changed: Form 8-K Current Report filed under Item 8.01 (Other Events) by Drugs Made In America Acquisition II Corp. The Company reports that, per its own disclosure, the sponsor made improper withdrawals from the working capital account between September 26, 2025, and December 31, 2025. The board of directors immediately took action to confirm these irregularities did not reach the trust account. Chief Executive Officer Roger Bendelac executed the filing, which states the trust account holds approximately $507,841,957 as of March 6, 2026. The report outlines no alterations to redemption windows, extension provisions, or business combination milestones. Why it matters: Sponsor-initiated working capital impropriety introduces governance and proxy-voting risk, signaling potential internal control deficiencies prior to a merger. However, because the board independently verified the diversion was confined to working capital, the full $507,841,957 trust pool remains available for shareholder redemptions, leaving the redemption floor unchanged from the filing's perspective. Reduced working capital may force reliance on external funding or trigger extension negotiations if operating expenses outpace remaining liquidity before a deal closes. The document provides no information on target prospects, customer relationships, revenue streams, market positioning, or technological assets beyond the fund irregularity and its verification.
What changed: SEC Form 8-K - Current report disclosing executive departures and appointments under Item 5.02. On October 8, 2025, Glenn Worman delivered a resignation notice effective that day from his positions as Chief Financial Officer and principal financial and accounting officer. Mr. Worman indicated the resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices. On November 17, 2025, the Company appointed Saleem Elmasri as the new Chief Financial Officer and principal financial and accounting officer, executing a Master Services Agreement (Consulting Agreement) with Titan Advisory Services LLC to provide these services. Why it matters: The filing transitions financial oversight to an outsourced specialist during the SPAC's 'SEARCHING' phase, prior to any business combination. Under the Consulting Agreement, the Company pays Titan Advisory Services LLC $3,500 per month, or $42,000 per year. Furthermore, Chief Executive Officer Lynn Stockwell shall transfer 100,000 shares of the Company’s ordinary shares to Mr. Elmasri upon engagement. The new CFO’s profile lists him as a CPA with 20 years of experience in financial and management consulting, beginning at PricewaterhouseCoopers and currently serving as Managing Partner at Titan Advisory Services LLC. Regarding SPAC mechanics, this personnel shift carries no implications for the redemption calendar, triggers no extension votes, leaves the trust value unchanged, and reveals no new deal progress, customer claims, revenue metrics, or litigation. Sponsor conduct remains unremarked upon beyond the standard equity compensation and indemnity expectations outlined for officers.
What changed: Form 10-Q (Quarterly Report) for Drugs Made In America Acquisition II Corp. for the quarter ended September 30, 2025, the first quarterly report following its initial public offering. The company completed its IPO of 50,000,000 units at $10.00 per unit on September 26, 2025, generating $500,000,000 in gross proceeds, which were placed in a trust account. Simultaneously, it sold 1,200,000 Private Placement Units to the sponsor and Cantor for $12,000,000. The trust account held $500,109,355 as of September 30, 2025, representing $10.00 per public share redemption value. The company has 24 months from the IPO closing to complete a business combination. Prior to the IPO, the sponsor surrendered 30,347,722 founder shares in February and May 2025, reducing its stake to 14,375,000 founder shares. The company reported a net loss of $143,558 for the nine months ended September 30, 2025, and has working capital of $219,011. Management identified material weaknesses in internal control over financial reporting due to limited personnel. Why it matters: This filing establishes the baseline trust value ($10.00 per share), the 24-month deadline (September 2027), and the sponsor's reduced ownership. It confirms no deal target has been selected and that the company is searching for a target in the pharmaceutical industry. The going concern disclosure and material weakness in internal controls are notable risk factors. The over-allotment option remains available, which could affect share count. The filing also details related party transactions, including the administrative services agreement and founder share lock-up provisions.
What changed: This document IS a Form 12b-25 (Notification of Late Filing), which is a routine compliance exhibit filed with the Securities and Exchange Commission. Regarding mechanics bearing on redemption deadlines, trust value, extensions, deal progress, or sponsor conduct: the filing contains zero provisions affecting the SPAC’s business combination timeline, redemption procedures, trust account calculations, or merger status. It does not request an extension of the combination deadline. Regarding other substance: Chief Executive Officer Lynn Stockwell states that the quarterly financial statements 'could not be completed in sufficient time to solicit and obtain the necessary review of the subject report and signatures thereto in a timely fashion.' She also certifies that all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months have been filed, and represents that the company anticipates 'no significant change in results of operations from the corresponding period for the last fiscal year.' The filing provides no data on customers, revenue, market size, strategy, technology, partnerships, or litigation. It was signed on November 14, 2025. Securities and Exchange Commission registrant Drugs Made In America Acquisition II Corp. has formally notified the Commission that its Quarterly Report on Form 10-Q for the period ended September 30, 2025, will miss the statutory deadline. Under Rule 12b-25(b), the registrant binds itself to file the complete report on or before the fifth calendar day following the original due date. Why it matters: Investors tracking redemption windows and governance transparency should log this procedural deferral. The delayed quarterly disclosure postpones public visibility into current cash balances, related-party loan activity, sponsor advancement schedules, and any unpublicized target outreach. The filing introduces no changes to per-share trust valuations, redemption mechanics, or merger contingency clocks.
What changed: This document is a U.S. Securities and Exchange Commission Form 4 insider ownership report submitted by Director Catherine Do for Drugs Made In America Acquisition II Corp. According to the filing, on September 26, 2025, Director Do acquired 100,000 shares via a transaction coded as 'other,' leaving her with exactly 100,000 shares afterward. The report does not state the purchase price, share class, funding source, or whether the blocks were traded on an exchange or privately negotiated. It contains no disclosures relating to the company’s trust account, the reported $10.28 per-share trust reserve, upcoming redemption deadlines, extension procedures, target acquisition progress, or sponsor conduct. Why it matters: Because the Form 4 attributes no strategic rationale or financing terms to the director’s purchase, the update reflects a routine change in individual holdings rather than a mechanical alteration to the SPAC’s capital structure. The transaction does not shift the $10.28 per-share trust value, extend any redemption window, influence business combination timelines, or modify sponsor voting power or lock-up obligations. Investors tracking trust liquidity, shareholder vote mechanics, or promoter alignment should note that unpriced, unlabeled insider acquisitions during the SEARCHING phase do not override prospectus-defined redemption protocols or guarantee impending deal execution.
What changed: Form 8-K Current Report disclosing the consummation of the initial public offering and private placement, accompanied by a balance sheet and notes to financial statements. Per Item 8.01 and the attached financial notes, the company reported the consummation of its IPO of 50,000,000 units at $10.00 per unit, generating aggregate gross proceeds of $500,000,000. Simultaneously, it closed a private placement of 1,200,000 units at $10.00 per unit, yielding $12,000,000 in proceeds purchased by Drugs Made In America Acquisition II LLC (700,000 units) and Cantor Fitzgerald & Co. (500,000 units). As of September 26, 2025, $500,000,000 was deposited into the trust account. The filing establishes a 24-month Combination Period to complete a business combination, discloses total transaction costs of $28,357,609 (broken down by management into $10,000,000 in cash underwriting fees, $17,500,000 in deferred underwriting fees, and $857,609 in other offering costs), and confirms the sponsor holds 14,375,000 founder shares, with up to 1,875,000 subject to forfeiture if the underwriters' 7,500,000-unit over-allotment option is not fully exercised. Note 10 attributes the subsequent repayment of the $325,000 promissory note and $208,731 due to the sponsor on September 29, 2025, to the company. Why it matters: This filing finalizes the SPAC's funding mechanics and definitive calendar for public shareholders, confirming that $500,000,000 is held in the trust account to back redemption obligations. Management stated the company intends to focus on the pharmaceutical industry but explicitly disclosed that no target has been selected and no substantive discussions have been initiated. Underwriters agreed to waive their right to the $17,500,000 deferred underwriting commissions if a business combination is not completed within the Combination Period, protecting trust value for redeeming investors. Independent auditor MaloneBailey, LLP raised a going concern matter, noting the company has incurred significant costs without generating operating revenues and faces mandatory liquidation if a deal is not consummated, which fundamentally alters the risk assessment for holders of the ordinary shares and rights listed on Nasdaq.
What changed: A routine compliance exhibit—specifically a Joint Filing Agreement (Exhibit 99.1) attached to a Schedule 13D, executed on October 1, 2025, by and between Drugs Made In America Acquisition II LLC and Lynn Stockwell. The filing alters nothing regarding redemption deadlines, trust value, extension mechanics, or deal progress. As authored by the signatories, it merely establishes procedural coordination permitting two reporting persons to submit a single Schedule 13D on their combined beneficial ownership of DMII ordinary shares under Rule 13d-1(k)(1). Each signatory accepts sole responsibility for the completeness and accuracy of information pertaining to themselves, disclaiming liability for the other's data unless they possess knowledge of its inaccuracy. Why it matters: The agreement discloses no customers, revenue projections, market size estimates, technology roadmaps, partnership terms, litigation posture, or executive shifts. Its only substantive signal is that Lynn Stockwell and the sponsor LLC are consolidating their 13D reporting obligations, indicating aggregated holdings that cross the statutory disclosure threshold. Without the primary Schedule 13D body—which would typically list aggregate shares owned, acquisition dates, price paid, and purpose of the transaction—investors cannot determine whether this reflects passive accumulation, a targeted warrant/cash position, or early merger-stage coordination. The filing does not shift the tracked $10.28 trust per share, initiate any extension vote, or alter the SEARCHING status. Materiality is assessed as low pending receipt of the parent filing's ownership tables.
What changed: Form 4 insider ownership report. This filing is a Form 4 insider ownership report. On 2025-09-26, director Myron W. Shulgan acquired 100,000 shares under the category 'other', resulting in exact post-transaction holdings of 100,000 shares. The document bears on sponsor conduct by recording a director purchasing equity while the issuer searches for a target, yet it contains no language altering redemption deadlines, trust account mechanics, extension proposals, or deal progress. No other factual claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel appear in the text. Why it matters: The reported transaction updates the insider register by adding 100,000 shares to director Myron W. Shulgan’s position, but introduces no modifications to the SPAC’s corporate governance, conversion rights, or funding timeline. Because the filing itself attributes zero explicit guidance on merger timing or trust preservation, it does not materially reprice investor expectations regarding redemption windows or sponsor dilution; it merely documents a pre-combination equity purchase by a named director.
What changed: A Form 4, defined as an insider ownership report. Per the Form 4 filed 2025-10-01 for Drugs Made In America Acquisition II Corp., reporting person and CFO Glenn C. Worman acquired 100,000 shares on 2025-09-26, resulting in 100,000 shares owned after the transaction. The filing does not amend redemption deadlines, adjust trust account valuation mechanics, propose extensions, advance a specific business combination target, or alter sponsor conduct protocols; it exclusively records the executive equity purchase. Why it matters: The disclosed acquisition reflects executive capital deployment during a SEARCHING phase anchored to a documented trust/share of $10.28, which tracks insider positioning but carries no binding effect on public redemption windows, target selection timelines, or trust distribution parameters. Beyond the CFO’s share accumulation, the report makes no assertions about customer concentrations, revenue trajectories, addressable market sizing, corporate strategy, underlying technology, channel partnerships, pending litigation, or subsequent personnel appointments. All cited metrics, dates, and party identifications are sourced strictly from the Filing text and the Form 4 submission metadata.
What changed: A Form 4 insider ownership report for Drugs Made In America Acquisition II Corp., filed October 1, 2025, documenting September 26, 2025, transaction activity by its 10% owner, Drugs Made In America Acquisition II LLC. Per the Form 4, Drugs Made In America Acquisition II LLC executed three transactions on September 26, 2025: an open-market purchase of 700,000 shares leaving it with 15,075,000 shares; an other disposition of 400,000 shares leaving it with 14,675,000 shares; and an open-market sale disposing of 7,966,667 shares leaving it with 6,708,333 shares. The filing does not amend or comment on the reported trust/share amount of $10.28, nor does it disclose any mechanics governing redemption deadlines, trust account drawdowns, extension voting procedures, or target combination progress. The document also contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or corporate personnel; those commercial and operational areas remain entirely unaddressed in this submission. All holdings, trade sizes, and dates are attributed solely to the Form 4 filings by Drugs Made In America Acquisition II LLC. Why it matters: Sponsor-class open-market buying and selling directly impacts observable liquidity and offers a transparent gauge of executive confidence while the SPAC searches for a deSPAC candidate. The sequential divestiture evident in the disclosed transactions lowers the reporting entity’s tracked stake to 6,708,333 shares, which alters monitored voting concentration and potential future financial commitment signaling ahead of any business combination deadline. Investors tracking redemption windows will note that the submission provides zero changes to trust distribution schedules or extension mechanics, meaning the calendar remains governed by the prospectus baseline. Nevertheless, the volume of disclosed trading activity may temporarily shift secondary market supply dynamics for the equity while the entity remains in SEARCHING status.
What changed: Form 4 insider ownership report. According to director, CEO and Executive Chair of the Board Stockwell Lynn, the filing records three transactions executed on 2025-09-26: an open-market acquisition of 700,000 shares, an “other” disposal of 400,000 shares, and an open-market disposal of 7,966,667 shares. The reporting person states his resulting holding is 6,708,333 shares. Why it matters: The exhibit does not modify redemption deadlines, alter the per-share trust balance, announce extension proposals, provide target discovery updates, or detail combination execution progress. Regarding sponsor conduct, the reported open-market sale of 7,966,667 shares by the chief executive shifts his registered position to 6,708,333 shares; this disposition is documented solely by the reporting person and contains no associated statements on corporate strategy, customer concentration, revenue forecasts, addressable market size, proprietary technology, strategic partnerships, litigation developments, or executive succession. Because the filing supplies only transaction ledger data without procedural calendar markers or valuation references, it does not change the operative mechanics tracked by redemption-focused investors.
What changed: A Form 4 insider ownership report. This document is a Form 4 insider ownership report filed on 2025-10-01. It reports that Director Prasad Sridhar G. acquired 100,000 shares on 2025-09-26 through a transaction coded as 'other,' resulting in post-transaction ownership of exactly 100,000 shares. No redemptions were triggered, the trust account balance was not amended, no extension votes were scheduled or passed, business combination progress remains undisclosed, and sponsor conduct shows no alterations per the filing. Beyond the director’s acquisition, the document contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or additional personnel movements. Why it matters: The filing documents direct capital deployment by a sitting director during an active search phase. For investors monitoring redemption calendars and trust mechanics, this report confirms zero impact on the trust account, no modifications to business combination deadlines, and unchanged sponsor forfeiture or compensation structures. The accumulation signals private conviction regarding eventual target selection or sponsor track record, but without disclosed pricing, settlement terms, or target identifiers, it does not alter public redemption windows or indicate imminent deal execution. Tracking this position alongside subsequent prospectus supplements or preliminary proxy materials remains essential for correlation.
What changed: Current Report on Form 8-K announcing the closing of the initial public offering (IPO) of Drugs Made In America Acquisition II Corp. and entry into associated definitive agreements. The SPAC completed its IPO of 50,000,000 units at $10.00 per unit, raising $500 million in gross proceeds, and simultaneously closed a private placement of 1,200,000 private units at $10.00 per unit generating $12 million. A total of $500 million was deposited into the trust account, establishing an initial trust value of $10.00 per public share. The company also appointed three independent directors, adopted an amended charter, and its units began trading on Nasdaq under DMIIU. Why it matters: This filing sets the baseline trust value at $10.00 per share and starts the 24-month deadline (to September 26, 2027) for a business combination. It details sponsor lock-up provisions (founder shares and private units subject to 6-month or $12.50 price-based lock-ups), redemption mechanics (public shareholders can redeem upon a business combination or liquidation if no deal, and amendments affecting redemption rights trigger additional redemption opportunities), and the sponsor’s indemnification of the trust account against certain claims. For investors monitoring redemption deadlines and trust value, the key numbers are established: $10.00 per share in trust, $17.5 million deferred underwriting commission, and up to $100,000 from interest for dissolution expenses. The company has not identified a target but intends to focus on pharmaceutical supply chain onshoring.
What changed: Prospectus filed pursuant to Rule 424(b)(4) — a final prospectus for an initial public offering of 50,000,000 units at $10.00 per unit by a newly-formed blank-check company searching for a pharmaceutical target, with the proceeds held in trust. This is the firm-commitment IPO prospectus for DMII. It describes a $500 million trust ($10.28 per share), a sponsor with 14.375 million founder shares (bought for $35,000), 1.2 million private units at $10.00 each, a 24-month completion window, and standard redemption mechanics (public holders may redeem at the trust value per share upon a business combination or liquidation). The sponsor has committed to purchase 700,000 private units; Cantor will purchase 500,000 private units. Up to 1.875 million founder shares may be forfeited if the over-allotment option is not exercised. No target, discussions, or LOI exist. Why it matters: This filing establishes all of the structural terms and deadlines that govern the SPAC: the exact trust value ($500M / 50M shares = $10.00 per share), the 24-month deadline, the no-redemption-rights for rights, the 15% cap on redemptions if a shareholder vote is used, and the significant dilution from founder shares purchased at $0.0024. It also flags related-party conflicts: Lynn Stockwell runs both DMII and DMAA (a sister SPAC), and DMII must present targets to DMAA first. The Chapter 11 filing of Bright Green Corporation (where Lynne Stockwell is CEO) and ongoing litigation against Lynn and John Stockwell are disclosed. These conflict and bankruptcy disclosures are material for assessing sponsor conduct and deal risk.
What changed: SEC Form 3, an insider ownership report and routine compliance exhibit disclosing the initial beneficial ownership stake of a sponsor affiliate. The filing reports that Drugs Made In America Acquisition II LLC holds 14,375,000 direct shares. This confirms the sponsor’s foundational equity position and does not alter the redemption deadline schedule, modify the trust account valuation mechanism, activate an extension provision, update business combination milestones, or reflect any change in sponsor conduct or lockup status. No transaction execution date, purchase price, or exercise ratio is documented. Why it matters: For investors monitoring redemption thresholds and sponsor alignment, the 14,375,000-share promoter block disclosed by Drugs Made In America Acquisition II LLC enables accurate dilution modeling upon a future business combination. According to the filing, the submission contains no operational claims regarding customer pipelines, recurring revenue forecasts, total addressable market sizing, proprietary technology roadmaps, commercial partnerships, active litigation exposures, or executive personnel adjustments attributed to the issuer’s management. The registrant’s representative filed this purely as a capitalization record, and it does not introduce new timelines or cash-flow implications for public shareholders.
What changed: A Form 3 initial statement of beneficial ownership, functioning as a routine compliance exhibit filed by director Prasad Sridhar G. for Drugs Made In America Acquisition II Corp. The document states 'No non-derivative transactions or holdings reported.' There are no changes to insider equity positions, nor does the filing disclose any developments affecting redemption calendar tracking, trust account valuation mechanics, extension voting procedures, merger target identification progress, or sponsor conduct. Why it matters: The exhibit contains no substantive operational disclosures. No claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel are attributed to management, board members, or sponsors. No numerical performance metrics or timeline updates appear beyond the form identifier and SEC reference number. The explicit absence of reported transactions confirms no covert insider positioning during the SEARCHING phase, though it delivers no forward-looking catalysts, revised distribution thresholds, or governance signals for public shareholders.
What changed: A Form 3 insider ownership report filed on September 24, 2025. The filing records no amendments to redemption deadlines, trust per-share values, extension proposals, or business combination progress. It states that reporting person Stockwell Lynn, identified as director, CEO, and Ex. Chair of the Board, holds 14,375,000 shares indirectly as of the filing date. Why it matters: Investors monitoring sponsor alignment and future deal-voting thresholds can use the disclosed 14,375,000 share count as the baseline for Stockwell Lynn’s economic interest during the SEARCH phase. Because the document reports only a static holding rather than a purchase or sale, it neither alters the public shareholders’ redemption window, impacts trust distributions, nor signals an imminent target announcement.
What changed: Form 3 — an initial SEC statement of beneficial ownership and routine compliance exhibit for a Spac director. The filing states that reporting person Myron W. Shulgan (director) has 'No non-derivative transactions or holdings reported.' Accordingly, there are no updates to insider equity positions, sponsor commitment levels, public market share purchases, warrant conversions, or financing arrangements that would impact redemption deadlines, trust account mechanics, extension votes, or target identification progress. No timeline modifications or capital events are documented. Why it matters: For investors tracking SPAC mechanics and sponsor conduct, this confirms Director Shulgan’s beneficial ownership status remains static with zero disclosed acquisitions or dispositions. The explicit notation of unreported holdings and transactions signals no recent shift in this director’s financial exposure or conviction signaling ahead of the ongoing search. As a routine compliance exhibit, the document contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, and therefore does not alter the issuer’s operational outlook, trust preservation requirements, or existing redemption and extension parameters.
What changed: A routine compliance exhibit (SEC Form 3 insider ownership report). The filing documents zero changes to insider security positions. According to the Form 3 submission, reporting person Glenn C. Worman (CFO) stated explicitly that there were 'No non-derivative transactions or holdings reported.' Consequently, there is no update to sponsorship activity, management equity alignment, or corporate governance shifts relative to the SPAC’s operational cadence. Why it matters: Although the Form 3 records no activity, it provides a verified baseline for sponsor and officer conduct monitoring. The absence of reported transactions indicates no recent accumulation or disposition of securities by the CFO, which helps investors gauge whether leadership remains aligned with public shareholders ahead of any target search, business combination, or redemption deadline. The filing does not modify, extend, or accelerate any redemption windows, alter trust account mechanics, trigger extension votes, or advance deal progress. Because it contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel changes, it offers no fundamental or valuation insights. Its sole utility is confirming routine Section 16 compliance and establishing the unadjusted starting point for tracking future insider trades.
What changed: Form 3 — Statement of Changes in Beneficial Ownership; an insider ownership report filed by director Catherine Do. This Form 3 insider ownership report states that no non-derivative transactions or holdings were reported by director Catherine Do. Bearing on the required mechanics, the filing contains no updates to redemption deadlines, trust account status, extension provisions, deal progress, or sponsor conduct. Regarding other substance, the document makes no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Why it matters: Although the report supplies no adjustments to the redemption calendar, trust valuation, or business combination timeline, it formally captures the director’s unchanged beneficial ownership position during the SEARCHING phase. For investors tracking insider conviction signals against the reported $10.28 per-share trust balance, the explicit zero-reporting notation serves as a baseline confirmation rather than a catalyst. The absence of transactional or operational disclosures means structural assumptions remain static until subsequent periodic or event-driven filings are submitted.
What changed: Routine compliance exhibit: SEC Form 8-A for Registration of Certain Classes of Securities Pursuant to Section 12(b) of the Securities Exchange Act of 1934. Drugs Made In America Acquisition II Corp. formally registered three security classes—Ordinary Shares ($0.0001 par value), Rights (each entitling the holder to receive one-tenth of one Ordinary Share), and Units (each consisting of one Ordinary Share and one Right)—for trading on The Nasdaq Stock Market LLC. The filing incorporates the security descriptions from the company’s Form S-1 (File No. 333-288791), initially filed July 21, 2025, and was executed on September 24, 2025, by Chief Executive Officer Lynn Stockwell. Why it matters: Mechanics: This filing does not establish a redemption deadline, modify the trust account balance of $10.28 per share, invoke an extension, advance a business combination timeline, or disclose sponsor conduct. The SPAC remains in a SEARCHING status, meaning no shareholder voting events or cash-out triggers have been activated. Substance: Beyond standard corporate formation and contact data—the registrant incorporated under Cayman Islands law, provides IRS Employer Identification No. 98-1815624, and lists 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 as principal executive offices—the document contains no operational, financial, or strategic claims. It makes no assertions about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel beyond the authorized signatory line. As a purely administrative listing registration, it updates exchange compliance without delivering actionable intelligence for redemption timing, trust valuation, or sponsor accountability.
What changed: A Rule 461 acceleration request filed with the SEC’s Division of Corporation Finance by Drugs Made In America Acquisition II Corp. seeking to bring its Registration Statement on Form S-1 (File No. 333-288791) into effect at 4:30 p.m. Eastern time on September 24, 2025. The filing reports zero adjustments to the $10.28 trust share value, announces no redemption deadline modifications, proposes no trust extension amendments, and discloses no change in target search status or sponsor conduct. Chief Executive Officer Lynn Stockwell exclusively submits an administrative request to expedite S-1 effectiveness through U.S. counsel Loeb & Loeb LLP; the Company makes no operational, financial, or strategic representations. Why it matters: Accelerating the S-1 declaration establishes the mechanical trigger for when public shares may legally trade and become subject to SPAC redemption rights, directly compressing the timeline for investor capital deployment decisions during the SEARCHING phase. By stipulating that Staff approval does not foreclose future Commission action nor relieve the Company of full disclosure responsibility, the filing frames deal progression strictly as an internal execution milestone rather than a secured business combination. The absence of substantive commercial claims means market positioning, revenue projections, partnership negotiations, or litigation risks remain unverified until a subsequent Definitive Proxy or Prospectus Supplement is filed, leaving redemption calculus and extension viability entirely dependent on subsequent filings and Nasdaq compliance maintenance.
What changed: A Rule 461 acceleration request submitted as an SEC CORRESP filing. This document is a registration statement acceleration request. Per the undersigned, Cantor Fitzgerald & Co. formally asks the SEC to accelerate the effective date of the Form S-1 (originally filed July 21, 2025) to 4:30 p.m. Eastern Time on September 24, 2025, or as soon thereafter as practicable. The filing advises that copies of the proposed preliminary prospectus will be distributed to each underwriter or dealer reasonably anticipated to participate in the security distribution. Cantor Fitzgerald & Co. states it has complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934. No updates are provided regarding redemption deadlines, trust value, extension triggers, or sponsor conduct. Why it matters: Accelerating the S-1 effective date advances the capital raise and deSPAC execution timeline, which directly precedes final pricing, underwriter allocation, and potential business combination announcements that would activate shareholder redemption windows. As reported by David Batalion, Managing Director, Investment Banking at Cantor Fitzgerald & Co., preliminary prospectus distribution to participating dealers is underway. The filing contains no additional substance regarding customer bases, revenue projections, market sizing, strategic pivots, technology developments, partnership agreements, ongoing litigation, or personnel changes.
What changed: A Securities and Exchange Commission correspondence (CORRESP) submitting the Company’s written response to SEC Staff comments dated September 15, 2025 regarding Amendment No. 2 to its Registration Statement on Form S-1. Per Loeb & Loeb LLP partner G. Alex Weniger-Araujo, the Amended Registration Statement was revised on pages 7, 12, 14, 25, and throughout to reconcile disclosures about the transfer of founder shares to certain accredited investors unaffiliated with the sponsor against the terms of the letter agreement (Exhibit 10.3). The updated prospectus clarifies whether these transferees qualify as “initial shareholders,” whether they hold the 20% post-offering ownership stake referenced on page 14, and whether they are parties to or bound by the lock-up and transfer restriction provisions in both the letter agreement and underwriting agreement. An updated Exhibit 10.3 was filed concurrently. The SEC Staff originally flagged discrepancies between the prospectus language on page 7 and the lack of signature blocks for these transferees in the originally filed Exhibit 10.3. Why it matters: This filing advances the S-1 qualification process for Drugs Made In America Acquisition II Corp., confirming that the company remains in a pre-business combination stage with no disclosed adjustments to redemption deadlines, trust accounting, or business combination timelines. Regarding sponsor conduct and deal mechanics, the explicit mapping of transferee status to existing lock-up covenants clarifies how founder equity will circulate post-merger and defines shareholder rights during the qualification window. The specific attention to Rule 14e-5 compliance for secondary purchases from public shareholders indicates the Company and SEC Staff are structuring potential tender-like interactions to align with federal market safeguards. No extension requests or changes to shareholder voting windows were reported. Lynn Stockwell is identified solely as Chief Executive Officer in the distribution list. All operational and structural assertions derive directly from the Company’s disclosure revisions, SEC Staff commentary, and counsel’s submission.
What changed: Amendment No. 3 to Registration Statement on Form S-1 (preliminary prospectus) for the initial public offering of Drugs Made In America Acquisition II Corp., a blank-check company searching for a pharmaceutical target. This amendment updates the prospectus with unaudited financial statements for the six months ended June 30, 2025, and includes the form of letter agreement among the company, its sponsor, and insiders (Exhibit 10.3). It also provides revised dilution tables, risk factors, and expanded disclosures on the sponsor's Bright Green Corp. Chapter 11 proceedings and related litigation. Why it matters: The filing sets forth the final terms of the $500 million SPAC IPO ($10.00 per unit), including trust mechanics, 24-month completion window, redemption rights (with a 15% cap if shareholder vote is used), and lock-up provisions. It also discloses material conflicts of interest (all officers/directors also serve DMAA, a sister SPAC), the sponsor's nominal cost basis ($0.0024 per founder share), and the ongoing BGXX bankruptcy and litigation involving CEO Lynn Stockwell and her spouse, which may affect management credibility and deal execution risk.
What changed: Amendment No. 2 to Registration Statement on Form S-1 (S-1/A), filed by Drugs Made In America Acquisition II Corp. to register its initial public offering of 50,000,000 units (plus up to 7,500,000 for over-allotment) at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-tenth of a share upon a business combination. It is a blank check company IPO registration statement, not yet effective, and contains no deal target, extension, or redemption deadline. The text is substantially the full preliminary prospectus. This is Amendment No. 2 to the S-1. The filing updates the preliminary prospectus with current financial data (as of June 30, 2025), revised dilution tables, updated sponsor share forfeitures (February and May 2025), updated litigation disclosures regarding Bright Green Corp. (now in Chapter 11), and updated officer/director biographies and conflict disclosures. No business combination target is identified; no redemption date is set. Why it matters: For investors tracking this pre-IPO SPAC: (1) Trust value is set at $10.00 per unit; (2) The SPAC has 24 months from closing to complete a deal; (3) Sponsor paid $35,000 for 14.375 million founder shares ($0.0024/share), creating massive potential dilution for public shareholders; (4) A material risk is disclosed: the CEO (Lynn Stockwell) and her spouse (John Stockwell, special advisor) are involved in a Chapter 11 proceeding and litigation at Bright Green Corp., and all officers/directors also serve DMAA, a competing SPAC with a pre-existing fiduciary obligation to receive deal opportunities before this SPAC. The filing signals current operations and conflicts but no new corporate action.
What changed: SEC Division of Corporation Finance comment letter regarding Amendment No. 2 to the Form S-1 registration statement for Drugs Made In America Acquisition II Corp. The SEC requires the issuer to reconcile revised prospectus disclosure on pages 137, 14, and 7 about transferring founder shares to unaffiliated accredited investors with the terms in Exhibit 10.3. The SEC asks whether these transferees qualify as initial shareholders bound by the stated 20% post-offering ownership representation, lock-up provisions, and transfer restrictions, and whether purchases from public shareholders would comply with Rule 14e-5. The letter notes the transferees do not appear as signatories to the letter agreement. The filing maintains the reported trust/share value of $10.28 and SEARCHING status without altering redemption calendars or extension terms. Why it matters: Scrutiny over founder share attribution, lock-up applicability, and secondary trading rules directly impacts sponsor conduct, control mechanics, and pre-combination equity liquidity. Unclear transfer restrictions or noncompliant secondary purchases could disrupt redemption expectations, complicate deal timing, and delay S-1 effectiveness. The Division’s request to update exhibits and clarify signatory status highlights enforcement focus on governance structures that investors track when evaluating trust preservation, extension viability, and sponsor alignment. The document contains no independent claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel beyond the addressee identification.
What changed: S-1/A (Amendment No. 1) — Registration statement under the Securities Act of 1933 for the initial public offering of Drugs Made In America Acquisition II Corp., a blank-check company formed to acquire a pharmaceutical business. This amendment updates the registration statement with unaudited financial statements for the six months ended June 30, 2025 (including cash of $4,394, net loss of $97,400), a pro forma dilution table reflecting the as-adjusted capitalization, revised share surrender/forfeiture history (sponsor forfeited 18,847,222 shares in Feb 2025 and 11,500,000 in May 2025, leaving 14,375,000 founder shares), updated sponsor loan balance ($297,292 as of June 30, 2025 vs. $250,100 as of Dec 31, 2024), and enhanced disclosure regarding Bright Green Corp.'s Chapter 11 filing (Feb 22, 2025) and the related Fikany litigation. The document also revises risk factors to reflect the sponsor's ongoing bankruptcy proceeding and updates the description of the company's business strategy and investment criteria. Why it matters: This is the foundational IPO registration for a $500 million SPAC targeting pharmaceutical acquisitions. Key mechanics for investors: the trust holds $10.00 per public share; shareholders have redemption rights upon business combination; the company has 24 months from closing to complete a deal; the sponsor's founder shares ($0.003 per share) create massive dilution and a conflict of interest; sponsor and officers are locked up for 6 months post-deal or until a $12.50 share price trigger; the sponsor's sole member Lynn Stockwell is also CEO of a parallel SPAC (DMAA) and involved in a Chapter 11 proceeding at Bright Green, raising sponsor conduct concerns. The filing provides the complete terms of the offering, including unit structure (one share plus one-tenth share right), underwriting discounts, deferred compensation, and the limitation on redemptions exceeding 15% of public shares if a shareholder vote is held.
What changed: Registration Statement on Form S-1 for initial public offering of a blank-check company (SPAC) – Drugs Made In America Acquisition II Corp. Initial filing of the S-1 registration statement for a proposed $500 million IPO of 50,000,000 units at $10.00 per unit (plus over-allotment). No prior registration or business combination target has been selected or discussed. Why it matters: Establishes all key mechanics for the SPAC: $10.00-per-share trust, 24-month completion deadline, redemption rights (with 15% cap if shareholder vote is used), no maximum redemption threshold, sponsor founder shares purchased for ~$0.0024 per share, private placement of 1,200,000 units to sponsor and Cantor, lock-up provisions, and disclosure of material conflicts including the overlapping management with DMAA (another SPAC still searching) and the Bright Green Corp. Chapter 11 and related litigation involving Lynn Stockwell and John Stockwell.
What changed: SEC Division of Corporation Finance correspondence (CORRESP) dated July 18, 2025, responding to a May 2, 2025 staff comment letter regarding Drugs Made In America Acquisition II Corp.’s Amendment No. 1 to a Draft Registration Statement on Form S-1. Per counsel G. Alex Weniger-Araujo of Loeb & Loeb LLP on behalf of Drugs Made In America Acquisition II Corp., no mechanical changes were reported. The filing notes only a disclosure revision on pages 134–135 of the Registration Statement addressing a conflict-of-interest comment regarding the reimbursement of out-of-pocket expenses and repayment of loans if a de-SPAC transaction is not completed. Redemption deadlines, trust value, extension mechanisms, deal progress, and sponsor conduct remain unaltered. Why it matters: According to the correspondence, the company updated its prospectus to satisfy Securities and Exchange Commission staff inquiries about potential conflicts when a merger fails. As confirmed by counsel, this marks continued progress through the regulatory comment cycle for the Form S-1 submission originally amended on April 25, 2025, but introduces no modifications to the redemption calendar, trust account accounting, or acquisition timeline.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.